Captor Therapeutics
Poland - WrocławBiotechnology
Focus: Captor Therapeutics is a Poland-based biotechnology company specializing in targeted protein degradation for oncology and high unmet medical needs. Founded in 2022 and publicly listed, the company is in early-stage clinical development with a single Phase 1 program.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Captor Therapeutics?
AI assessmentCaptor is a speculative early-stage play suited only for risk-tolerant professionals seeking deep scientific involvement in an emerging modality, not career stability or near-term growth.
Why Work Here
- Access to cutting-edge targeted protein degradation technology, a rapidly advancing modality attracting significant industry investment
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
1 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT06994572Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma
Phase 1Help build intelligence for Captor Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.